Vanda Pharmaceuticals (VNDA) Operating Income (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly Operating Income of -$50.2 million in Q1 2026, down 24.46% quarter-over-quarter from -$40.4 million in Q4 2025, and down 22.41% year-over-year from -$64.7 million in Q1 2025.
Vanda Pharmaceuticals' Operating Income history runs 17 years deep, the most recent figure standing at -$50.2 million for Q1 2026.
- In Q1 2026, Operating Income fell 22.41% year-over-year to -$50.2 million; the TTM figure through Mar 2026 stood at -$160.4 million (down 121.34% YoY), while the FY2025 annual figure was -$151.2 million, down 271.79% from the prior year.
- Operating Income came in at -$50.2 million for Q1 2026 at Vanda Pharmaceuticals, down from -$40.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $6.6 million in Q4 2022 to a low of -$50.2 million in Q1 2026.
- A 5-year average of -$14.7 million and a median of -$9.2 million in 2024 frame the typical range for Operating Income.
- Across the five-year window, Operating Income surged 126.13% in 2023 and slumped 560.83% in 2024, its largest moves.
- Vanda Pharmaceuticals' Operating Income stood at $6.6 million in 2022, then slumped by 207.01% to -$7.1 million in 2023, then tumbled by 44.9% to -$10.3 million in 2024, then tumbled by 292.58% to -$40.4 million in 2025, then slipped by 24.46% to -$50.2 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$50.2 million, -$40.4 million, and -$31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -50.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.22 Mn |
| Dec 31, 2025 | -40.35 Mn |
| Sep 30, 2025 | -31.28 Mn |
| Jun 30, 2025 | -38.50 Mn |
| Mar 31, 2025 | -41.03 Mn |
| Dec 31, 2024 | -10.28 Mn |
| Sep 30, 2024 | -11.00 Mn |
| Jun 30, 2024 | -10.15 Mn |
| Mar 31, 2024 | -9.24 Mn |
| Dec 31, 2023 | -7.09 Mn |
| Sep 30, 2023 | -6.00 Mn |
| Jun 30, 2023 | -2.87 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 6.63 Mn |
| Sep 30, 2022 | 3.91 Mn |
| Jun 30, 2022 | 3.46 Mn |
| Mar 31, 2022 | -7.67 Mn |
| Dec 31, 2021 | 8.64 Mn |
| Sep 30, 2021 | 10.82 Mn |
| Jun 30, 2021 | 12.37 Mn |
| Mar 31, 2021 | 10.34 Mn |
| Dec 31, 2020 | 10.45 Mn |
| Sep 30, 2020 | 7.74 Mn |
| Jun 30, 2020 | 9.17 Mn |
| Mar 31, 2020 | -125,000.00 |
| Dec 31, 2019 | 4.24 Mn |
| Sep 30, 2019 | 10.76 Mn |
| Jun 30, 2019 | 9.90 Mn |
| Mar 31, 2019 | -2.09 Mn |
| Dec 31, 2018 | 9.15 Mn |
| Sep 30, 2018 | 6.23 Mn |
| Jun 30, 2018 | 3.91 Mn |
| Mar 31, 2018 | 2.44 Mn |
| Dec 31, 2017 | -2.15 Mn |
| Sep 30, 2017 | -4.92 Mn |
| Jun 30, 2017 | -1.92 Mn |
| Mar 31, 2017 | -7.91 Mn |
| Dec 31, 2016 | -654,000.00 |
| Sep 30, 2016 | -653,000.00 |
| Jun 30, 2016 | -4.79 Mn |
| Mar 31, 2016 | -12.48 Mn |
| Dec 31, 2015 | -14.89 Mn |
| Sep 30, 2015 | -9.54 Mn |
| Jun 30, 2015 | -5.46 Mn |
| Mar 31, 2015 | -10.29 Mn |
| Dec 31, 2014 | 69.69 Mn |
| Sep 30, 2014 | -1.45 Mn |
| Jun 30, 2014 | -21.61 Mn |
| Mar 31, 2014 | -26.58 Mn |
| Dec 31, 2013 | -7.79 Mn |
| Sep 30, 2013 | -5.43 Mn |
| Jun 30, 2013 | -3.41 Mn |
| Mar 31, 2013 | -4.57 Mn |
| Dec 31, 2012 | -6.43 Mn |
| Sep 30, 2012 | -5.40 Mn |
| Jun 30, 2012 | -8.09 Mn |
| Mar 31, 2012 | -8.32 Mn |
| Dec 31, 2011 | -5.91 Mn |
| Sep 30, 2011 | -3.29 Mn |
| Jun 30, 2011 | -1.51 Mn |
| Mar 31, 2011 | 7,000.00 |
| Dec 31, 2010 | 791,000.00 |
| Sep 30, 2010 | 743,000.00 |
| Jun 30, 2010 | 1.16 Mn |